The mechanisms by which telomeres are distinguished from DNA double-strand breaks are poorly understood. Here we have defined the minimal requirements for the protection of telomeric DNA ends from nonhomologous endjoining (NHEJ). Neither long, single-stranded overhangs nor t loop formation is essential to prevent NHEJ-mediated ligation of telomeric ends in vitro. Instead, a tandem array of 12 telomeric repeats is sufficient to impede illegitimate repair in a highly directional manner at nearby DNA ends. The polarity of end protection is consistent with the orientation of naturally occurring telomeres and is well suited to minimize interference between chromosome capping and the repair of DNA double-strand breaks in subtelomeric sequences. Biochemical fractionation and reconstitution revealed that telomere protection is mediated by a RAP1/TRF2 complex, providing evidence for a direct role for human RAP1 in the protection of telomeric DNA from NHEJ.
INTRODUCTION
The efficient repair of DNA double-strand breaks (DSBs) is essential for the maintenance of genome stability in all organisms. Homologous recombination (HR) and nonhomologous end-joining (NHEJ) are the two principal pathways that repair such lesions (Wyman and Kanaar, 2006) . Homologous recombination is a highly accurate repair pathway that employs a homologous template sequence to restore information lost at the site of a break (West, 2003) . It is predominantly active during S and G2 phases of the cell cycle when a sister chromatid is available as a template. In NHEJ, the two DNA ends are simply rejoined, a mechanism that is error prone as the damaging event or subsequent processing may result in the loss of nucleotides on either side of the break (Burma et al., 2006) . NHEJ is active throughout the cell cycle but is thought to be the dominating pathway in G1 when no sister chromatid is available as template for homologous recombination ).
An interesting problem arises in cells with linear genomes, as the natural ends of chromosomes must be distinguished from DNA breaks and protected from undergoing fusion with each other or sites of DNA damage. Specialized nucleoprotein structures, known as telomeres, protect chromosome ends from illegitimate repair as well as from gradual attrition due to the end replication problem (Cech, 2004; Hug and Lingner, 2006) . In most eukaryotes, telomeres are comprised of GT-rich repeat sequences with the GT-rich strand always oriented in the 5 0 to 3 0 direction toward the chromosome end. This uniform orientation of a tandem repeat sequence prevents chromosome fusions via homologous recombination. Instead, HR events can elongate and shorten telomeres and may thereby contribute substantially to telomere maintenance (Lundblad, 2002) . In contrast, NHEJ between telomeres results in genomic instability, mitotic catastrophe, and frequently cell death (Karlseder et al., 1999; van Steensel et al., 1998) .
The mechanism by which NHEJ is prevented from acting on chromosome ends has been a matter of considerable interest for some time. Over the past 20 years, proteins that specifically localize to telomeres have been identified in a number of organisms. In vertebrates, double-stranded telomeric repeats are directly bound by the homeodomain proteins TRF1 and TRF2 (Bilaud et al., 1997; Broccoli et al., 1997; Court et al., 2005; Chong et al., 1995) . These recruit TIN2 (Kim et al., 1999) , which via TPP1 (Houghtaling et al., 2004; Liu et al., 2004; Ye et al., 2004) can form a bridge with POT1 (Baumann and Cech, 2001) , the protein that specifically binds to the single-stranded 3 0 overhang at the end of the G-rich strand (Baumann et al., 2002; Loayza and de Lange, 2003) . TRF2 also interacts directly with RAP1 and POT1 Yang et al., 2005) . These six proteins have been referred to as the shelterin complex (de Lange, 2005) , indicating a role in protecting the chromosome end from repair activities, as much as in negatively regulating telomerase by sequestering its DNA substrate in a closed conformation.
Surprisingly, numerous proteins with known roles in DNA repair are also involved in telomere maintenance. The Ku heterodimer, the Mre11-Rad50-Nbs1 (MRN) complex, ATM, and several other proteins described as damage sensors, checkpoint proteins, and repair factors have been implicated in normal telomere function (d'Adda di Fagagna et al., 2004) . Further blurring the distinction between telomere maintenance and DNA repair are the recent findings that the telomere-binding protein TRF2 and its fission yeast homolog Taz1 may be directly involved in DSB repair in addition to their roles at telomeres (Bradshaw et al., 2005; Miller and Cooper, 2003) .
Over the past two decades several mechanisms for chromosome end protection have been proposed. Possibly the most elegant solution to establishing an inaccessible state of a telomere is the remodeling of linear DNA into telomeric loops (t loops), structures in which the terminal single strand invades internal regions of the same telomere. Such structures have been isolated from several organisms and visualized by electron microscopy (de Lange, 2004; Griffith et al., 1999) . Purified TRF2 can facilitate t loop formation in vitro (Stansel et al., 2001 ) and may do so alone or as part of a complex in vivo. It is presently unclear whether all telomeres or only a subset adopt the t loop conformation, and whether these structures persist for most of the cell cycle or appear transiently, possibly as intermediates of telomere rapid deletion events (Ancelin et al., 2002; Lustig, 2003; Wang et al., 2004) . Chromatin immunoprecipitation experiments revealed that DNA damage response factors are recruited to telomeres in G2 (Verdun et al., 2005; Verdun and Karlseder, 2006) . These results support a model in which chromosome ends are transiently recognized as DNA breaks after replication and are then converted into a stable structure by a process that requires telomere-binding proteins and the homologous recombination machinery.
Expression of mutant proteins and RNAi-mediated knockdown experiments have implicated several proteins in telomere capping. For example, knockdown of human POT1 was found to cause an increase in chromosome end fusions (Hockemeyer et al., 2005; Veldman et al., 2004; Yang et al., 2005) . Similarly, knockout of POT1a and POT1b in mouse embryonic fibroblasts resulted in chromosomal abnormalities Hockemeyer et al., 2006; Wu et al., 2006) . Surprisingly, a comparable increase in chromosome end fusions is also observed in cells defective in Ku, DNA-PK cs , or Artemis, all proteins involved in DSB repair by NHEJ (reviewed in ). The mechanism by which these proteins function in telomere capping has remained largely enigmatic, but a high-affinity interaction between Ku and TRF1 has been suggested to prevent NHEJ uniquely at telomeres (Hsu et al., 2000) . Consistent with such a mechanism, telomere fusions have been observed following conditional deletion of TRF1 in ES cells (Iwano et al., 2003) , although another study found no evidence of telomere uncapping in chromosome spreads from TRF1 À/À blastocysts (Karlseder et al., 2003) .
Arguably, the most dramatic incidence in chromosome fusions has been associated with expression of TRF2 DBDM , a dominant-negative mutant of TRF2 (van Steensel et al., 1998) . Displacement of endogenous TRF2 from telomeres by TRF2
DBDM resulted in abundant ligase IV-dependent telomere fusions (Smogorzewska et al., 2002) . A conditional knockout of TRF2 in mouse embryonic fibroblasts revealed an even more dramatic phenotype with virtually all telomeres engaged in end-to-end fusions (Celli and de Lange, 2005) . These observations argue for a key role for TRF2 in distinguishing telomeres from DNA DSBs. It is presently unknown whether the protection of telomeres from NHEJ by TRF2 is linked to its ability to promote t loop formation. Single telomere length analysis (STELA) suggested that a fraction of human telomeres are too short for t loop formation but may still be protected from undergoing fusions (Baird et al., 2003) . These ultrashort telomeres can be comprised of fewer than ten repeats and are thought to arise as a result of catastrophic telomere deletion events.
Here we show that fewer than 10 telomeric repeats can indeed be sufficient to provide protection against illegitimate fusions by NHEJ. Protection is mediated by a RAP1/TRF2 complex that inhibits DNA-PK-and ligase IV-mediated end-joining specifically on the 3 0 side of telomeric repeats. As RAP1 has been shown to function in NHEJ suppression in fission and budding yeast, our data indicate that an evolutionarily conserved mechanism may mediate the protection of telomeres from yeast to man.
RESULTS

Inhibition of NHEJ at Telomeric DNA Ends
An in vitro assay for DSB repair has been developed and recapitulates the in vivo requirement for NHEJ in that end-joining is dependent on the Ku heterodimer, DNA-PK cs , and XRCC4/ligase IV (Baumann and West, 1998) . This system has been used extensively to study the mechanism of NHEJ and to demonstrate the involvement of polynucleotide kinase, nucleases, and polymerases in the processing of ends prior to ligation (Budman and Chu, 2005; Chappell et al., 2002; Hanakahi et al., 2000; Huang and Dynan, 2002) . To define the minimal requirements for protection of chromosome ends from NHEJ, we added short arrays of telomeric repeats to a 3 kb nontelomeric DNA substrate ( Figure 1A) . As a control, arrays of scrambled telomeric repeats (TGAGTG) were introduced into the same plasmid. When introduced into the end-joining assay, $32% of the control substrate was ligated into dimers, trimers, and longer concatemers (Figure 1B, lanes 2-4) . This efficiency of end-joining is similar to what had previously been reported with other DNA substrates (Baumann and West, 1998; Chappell et al., 2002) , suggesting that NHEJ is not inhibited by G-rich repeat sequences in general. In contrast, only 8% of a substrate containing 12 telomeric repeats at one end underwent end-joining, and only dimeric products were observed (lanes 6-8). It thus appears that the presence of a short array of telomeric repeats can inhibit NHEJ.
To verify that end-joining in these reactions is indeed catalyzed by the same proteins that mediate NHEJ in vivo, a number of control reactions were carried out. Consistent with a requirement for DNA-PK activity, wortmannin inhibited the end-joining reaction in a concentration-dependent manner ( Figure 1C ). End-joining with telomeric and nontelomeric DNA substrates was also reduced following the addition of blocking antibodies against the Ku70/80 heterodimer ( Figure 1D ). A requirement for XRCC4/ligase IV was confirmed by the addition of blocking antibodies against XRCC4 as well as by immunodepletion ( Figure 1E and data not shown). We have thus confirmed that endjoining in these reactions is dependent on DNA-PK cs , Ku, and XRCC4/ligase IV as previously reported (Baumann and West, 1998) .
The observation that end-joining was greatly reduced in the presence of 12 telomeric repeats indicated that activities in the cell extract recapitulate the protection of chromosome ends from NHEJ. Only one end of the DNA substrate used here was telomeric (subsequently referred to as head); the other was nontelomeric (tail). Ligation products may result from tail-to-tail, head-to-tail, and headto-head fusions ( Figure 2A ). The orientation of monomers in the ligation products is revealed by asymmetric digestion with ScaI (site indicated by an S in Figure 2A ). As expected, all three types of fusions were recovered with the control substrate containing scrambled telomeric repeats ( Figure 2B , lane 3). However, only tail-to-tail fusions were observed with the telomeric substrate (lane 4), demonstrating that telomeric ends did not engage in fusions with each other (head-to-head) or with nontelomeric ends (head-to-tail). The absence of trimers and longer concatemers is explained by tail-to-tail fusions giving rise to linear dimers with two telomeric ends, which are thus protected at both ends from further ligation reactions. Indeed, when a DNA substrate containing telomeric repeats at both ends was used, end-joining was inhibited (see Figure S1A in the Supplemental Data available with this article online, lanes 2-4). Our results thus suggest that the presence of a few telomeric repeats is sufficient to prevent NHEJ at a nearby DNA end.
Minimal Requirements for Inhibition of NHEJ
We next examined how many repeats are required to protect a DNA terminus from NHEJ. For this purpose a series of linear DNA substrates with 2-24 telomeric repeats at one end were generated and tested in the end-joining assay. The presence of up to six telomeric repeats did not impair end-joining as indicated by the formation of dimers, trimers, and tetramers ( Figure 2C , lanes 2, 4, and 6). In contrast, 12 or more telomeric repeats prevented fusions involving telomeric ends and only tail-to-tail products were detected ( Figure 2C , lanes 8 and 10). Intermediate levels of protection were observed in the presence of eight and ten telomeric repeats ( Figure S1B ). Varying the number of scrambled telomeric repeats had no effect on end-joining efficiency (data not shown). We considered several mechanisms that could prevent NHEJ of telomeric ends. First, the machinery responsible for NHEJ may not assemble on telomeric DNA. We consider this possibility unlikely as the Ku heterodimer binds to telomeric DNA in vitro and NHEJ-mediated joining of telomeric DNA ends has (C) DNA substrates terminating on the 3 0 side with the indicated number of TTAGGG repeats were subject to standard end-joining reactions.
(D) Ligation of telomeric DNA ends by T4 DNA ligase. EcoRI-digested pNB146 was incubated in standard end-joining reactions prior to incubation with T4 DNA ligase (10 units) for 1 hr at 37 C. DNA substrate (linear) and ligation products are labeled on the right; abbreviations are rc (relaxed circle) and sc (supercoiled circle).
(E) Positioning of telomeric repeats. TTAGGG or scrambled repeats were either positioned at the 3 0 terminus (lanes 1 and 5) or internally so that the indicated number of nontelomeric base pairs were present between the last repeat and the terminus.
(F) Schematic of DNA substrates with repeats at 5 0 or 3 0 end.
(G) DNA substrates shown in (F) and scrambled controls were incubated in standard end-joining reactions.
been observed in cells expressing a dominant-negative version of TRF2 (Smogorzewska et al., 2002) . Second, telomeric DNA may be specifically processed into a structure that is incompatible with ligation, such as long singlestranded overhangs. Instead or in addition, the G-rich strand may adopt G-quadruplex structures that would render the 3 0 end inaccessible to ligation. We can exclude the possibility that exonucleolytic degradation of the C-rich strand generated long 3 0 overhangs, as the radiolabeled terminal 5 0 phosphate was retained equally well on telomeric and nontelomeric ends (e.g., Figure 1B ). Furthermore, the ability of T4 DNA ligase to join telomeric ends was only slightly impaired by prior or simultaneous incubation with human cell-free extract ( Figure 2D and data not shown). It therefore appears unlikely that telomeric DNA end processing or structural modifications account for the protection from NHEJ in this assay.
Further characterization of telomere-specific inhibition of NHEJ revealed that end-joining was blocked even when the terminal sequence was nontelomeric ( Figure 2E ). Inhibition was as efficient whether the DNA substrate terminated in telomeric repeats (lane 5) or whether 25 nontelomeric nucleotides were present between the telomeric repeats and the 3 0 end (lane 7). Addition of 44 nucleotides of nontelomeric sequence restored end-joining to the same level as seen in the absence of telomeric sequence (compare lanes 4 and 8). The protective effect exerted by telomeric repeats therefore extends over some distance, suggesting that sequence-specific end-binding is not required for telomere capping.
In vivo, all telomeres have the same polarity with the G-rich sequence representing the strand that contributes the 3 0 terminus at each chromosome end. Placing the TTAGGG sequence at the 3 0 end of the end-joining substrate therefore mimics a natural chromosome end, whereas a 5 0 -TTAGGG end would only be found in cells as the consequence of a DNA break proximal to a telomere ( Figure 2F ). A comparison of the two possible orientations revealed that only the TTAGGG-3 0 orientation provided protection from NHEJ, whereas a 5 0 -TTAGGG terminus was joint as efficiently as a nontelomeric substrate (Figure 2G) . Protection of telomeric DNA ends from NHEJ in vitro therefore has a defined polarity consistent with the protection of natural chromosome termini.
TRF2, but Not TRF1 or Ku, Protects Telomere Ends Several proteins have been implicated in chromosome capping based on chromosomal aberrations observed in mutant cells or as a result of RNAi-mediated knockdown. We were particularly interested in the role of Ku in maintaining telomere integrity, as telomere fusions have been reported for Ku70 and Ku80 mouse knockout cells (d'Adda di Fagagna et al., 2001; Hsu et al., 2000; Samper et al., 2000) . Immunodepletion of Ku by $80% ( Figure 3A , lane 2) abolished NHEJ-mediated fusions of nontelomeric ends ( Figure 3B, lane 7) . However, no fusions between telomeric ends were detected either (lane 2). Instead, we observed reduced protection of all DNA ends as evidenced by the loss of terminal radiolabel from the DNA substrates ( Figure 3B , compare signals for monomers). These observations are consistent with a model in which Ku protects DNA ends at break sites as well as chromosome termini. In the absence of Ku, another DNA repair pathway not reconstituted in this assay may be engaged and account for telomere fusions observed in Ku À/À cells in vivo.
Depletion of the telomere repeat binding factors TRF1 and TRF2 ( Figure 3A , lanes 4 and 5) resulted in loss of telomere protection. Using fractions in which TRF1 and TRF2 were reduced to below the limit of detection (<2%), telomeric ends were joined as efficiently as nontelomeric ends ( Figure 3B , compare lanes 4 and 5 with lanes 9 and 10). Depletion with an antibody raised against human RAP1 resulted in the concomitant loss of TRF1 and TRF2, consistent with the idea that these proteins interact with each other as part of the shelterin complex ( Figure 3A, lane 3) . Again, the depleted fraction failed to protect telomeric ends and supported efficient ligation of all substrates (Figure 3B, lanes 3 and 8) . Robust end-joining was also observed with DNA substrates containing telomeric repeats at both ends ( Figure S1A , lane 5). We surmised that our in vitro system recapitulates the requirement for TRF2 in chromosome end protection.
It is a matter of great interest whether end protection in cells is mediated by TRF2 alone, the shelterin complex, or TRF2 in association with other factors. To address this issue biochemically we expressed and purified recombinant versions of TRF1 and TRF2 ( Figure S2B ). Telomeric DNA-binding activity was verified for both proteins in electrophoretic mobility shift assays (data not shown). Despite efficient binding to the substrate DNA, the addition of up to 150 fmol of TRF1 did not impair end-joining of telomeric substrates ( Figure 3C ). In contrast, addition of only 15 fmol of TRF2 inhibited joining reactions involving telomeric ends ( Figure 3D ). Quantitative western analysis showed that this amount of TRF2 corresponds to the amount of endogenous TRF2 present in untreated cell extract ( Figure S2C ). Despite the ability of TRF2 to also interact with nontelomeric DNA (Amiard et al., 2007 ; our unpublished data), adding TRF2 had no effect on end-joining of nontelomeric control substrates ( Figure 3D , lanes 7-10).
TRF2 Is Required, but Not Sufficient, for Telomere Protection TRF2-depleted fractions also showed a reduced level of RAP1 ( Figure 3A, lanes 4 and 5) . This is consistent with the idea that RAP1 is recruited to telomeres via a direct interaction with TRF2 . Depletion of TRF2 reduced the level of RAP1 by $50%, suggesting that not all RAP1 exists in a complex with TRF2 or that the RAP1-TRF2 interaction is disrupted during immunoprecipitation. In agreement with the former possibility and the proposed 1:1 stoichiometry (Zhu et al., 2000) , a molar excess of RAP1 over TRF2 was detected in cell extracts ( Figures  S2C and S2D ). When RAP1 was immunodepleted, RAP1 and TRF2 levels were reduced by more than 90% (Figure 3A, lane 3) .
Fractions depleted of RAP1 (and thereby TRF2) supported efficient end-joining of telomeric termini ( Figure 4A , lane 2). Interestingly though, the addition of recombinant TRF2 to endogenous levels did not restore the protection of telomeric DNA ends in RAP1-depleted fractions (lanes 3-6). Telomere protection was apparently restored when recombinant TRF2 was added at a 200-fold higher concentration ( Figure 4B, lane 4) . However, under these conditions the specific polarity of protection was lost and end-joining was also inhibited at 5 0 telomeric DNA termini, suggesting a nonspecific sequestration of DNA substrates (lane 8). In summary, these results suggest that specific protection of 3 0 telomeric ends from NHEJ requires more than just TRF2.
To identify factors that may cooperate with TRF2 in mediating the protection of 3 0 telomeric ends, we purified TRF2 from HeLa cell nuclear extract ( Figure 5A ). The elution profile of the final gel filtration step revealed that TRF2 was part of a complex with an apparent molecular weight of $650 kDa ( Figure 5B ). In contrast, purified recombinant TRF2 was found to elute in a single peak at an apparent molecular weight of $440 kDa. TRF2 has previously been reported to be a dimer in solution but elute at a much higher apparent molecular weight on gel filtration due to the presence of a long unstructured linker in each subunit (Court et al., 2005) . A nonglobular shape of TRF2 was also supported by sucrose gradient centrifugation analysis (our unpublished data).
Unlike recombinant TRF2, the endogenous TRF2 complex efficiently restored protection of 3 0 telomeric ends from NHEJ ( Figure 5C ). Analysis by western blotting and mass spectrometry revealed that the $650 kDa TRF2 complex contained RAP1, but not TRF1, TIN2, or POT1 ( Figure 5B and data not shown). When recombinant RAP1 was purified ( Figure S2B ) and incubated with TRF2 a stable complex was formed that was easily separated from excess TRF2 by anion exchange chromatography (data not shown). This reconstituted RAP1/TRF2 complex eluted in two overlapping peaks from a Superdex 200 gel filtration column, with the major peak coinciding with the elution profile of the endogenous TRF2 complex ( Figure 5B ). Although we cannot exclude the possibility that elution of the recombinant and endogenous TRF2 complexes in equivalent fractions is coincidental, the results suggest that the endogenous TRF2 complex may be solely comprised of RAP1 and TRF2.
Addition of recombinant RAP1 to RAP1-depleted endjoining reactions did not restore the protection of telomeric ends ( Figure 6A ). However, when purified RAP1 and TRF2 were added together, the telomeric ends were again protected from NHEJ ( Figure 6B, lanes 7-9) . Like the effect observed with endogenous factors, protection by the reconstituted RAP1/TRF2 complex was highly directional, affecting only DNA ends where the G-rich strand contributes the 3 0 terminus ( Figure 6C ). Taken together, our data support a critical role for a RAP1/TRF2 complex in capping short telomeres and protecting them from endto-end fusions.
DISCUSSION
The finding that a biochemical assay for DNA repair by NHEJ also recapitulates telomere capping provides an opportunity to gain mechanistic insights into chromosome end protection. We have shown here that the efficient protection of telomeric DNA ends from NHEJ requires a complex comprised of RAP1 and TRF2. While TRF2 has previously been implicated in telomere capping, this work provides evidence for a direct role of human RAP1 in the protection of telomeres from NHEJ. It is presently unknown whether other factors from the end-joining fraction cooperate with the RAP1/TRF2 complex in the protection of telomeric ends.
Perhaps our most unexpected finding is that a relatively small number of telomeric repeats are sufficient to prevent NHEJ from acting on a nearby DNA end. Human telomeres average over 1000 TTAGGG repeats, but NHEJ-mediated fusions were undetectable in the presence of 12 repeats ( Figure 2C ). This observation is at odds with a model of telomere protection in which t loop structures are required to protect chromosome ends from NHEJ, as the telomeres used here are far too short for loop formation. The finding that such short telomeres are nevertheless protected from NHEJ indicates that cells may use more than one pathway to safeguard chromosome ends. Analyses of mutant and knockout cell lines as well as RNAi experiments have implicated numerous factors in the protection of chromosome ends including TRF1, TRF2, POT1, Ku, DNA-PK cs , Artemis, Apollo, PARP, and RAD50 Lenain et al., 2006; van Overbeek and de Lange, 2006) . The involvement of so many proteins suggests that multiple pathways cooperate to ensure the integrity of all chromosome ends despite dynamic differences in telomere length and structure. Notably, STELA revealed that a subset of human telomeres is indeed as short as eight repeats (Baird et al., 2003) . We propose that these extremely short telomeres may be protected from undergoing NHEJ-mediated fusion by the RAP1/TRF2-dependent mechanism described here. In addition, the same mechanism may also be responsible for the protection of longer telomeres when they are in an open conformation, such as immediately after replication.
TRF2 seems to play a central role in protecting the majority of telomeres in mouse and human cells. This has in part been attributed to its t loop promoting activity (Stansel et al., 2001 ). In addition, TRF2 has been shown to bind the ATM kinase and block its activation, a mechanism by which a DNA damage response may be inhibited locally at telomeres where TRF2 is abundant (Karlseder et al., 2004) . This raises the interesting question whether TRF2 partially compromises the repair of breaks in subtelomeric DNA by locally weakening the DNA damage response. Consistent with such an effect, studies in budding yeast showed that a checkpoint response triggered by a DSB is inhibited in the vicinity of telomeric repeats (Michelson et al., 2005) . Collectively, these findings predict that subtelomeric DNA may be particularly vulnerable to DNA damage. It is important to note in this context that the mechanism of telomere protection described here shows a strong polarity, whereby end-joining is only inhibited at DNA ends 3 0 to the TTAGGG repeats. As the G-rich strand is oriented in the 5 0 to 3 0 direction on all naturally occurring telomeres, this mechanism of telomere capping would not interfere with the repair of breaks upstream of telomeric repeats.
The strict polarity in end protection is surprising in light of what is known about the DNA-binding mode of TRF2. A binding site for a TRF2 homodimer contains two YTAGGG TTR half-sites, each bound by one homeodomain (Broccoli et al., 1997; Court et al., 2005) . As each DNA-binding domain is connected to the dimerization domain by a long, highly flexible linker, DNA-binding affinity is thought to be unaffected by the relative orientation and, to a certain extent, spacing of the two half-sites (Fairall et al., 2001) . It should therefore be expected that a tandem array of 12 telomeric repeats is bound equally well near the 5 0 or 3 0 end of a DNA substrate. Indeed, gel retardation assays confirmed that TRF2 and the RAP1/TRF2 complex bind both substrates (our unpublished data), yet inhibition of NHEJ was only observed when a DNA end was present on the 3 0 site of the TTAGGG repeats ( Figure 2G ). A preference for TRF2 to bind DNA ends has previously been reported (Stansel et al., 2001) , but this study did not address whether TRF2 preferentially bound a 3 0 over a 5 0 telomeric end. Rather, terminal binding was found to be dependent on the presence of a telomeric double-strand to single-strand transition, a property that is at least in part mediated by the N-terminal basic domain of TRF2 (Fouche et al., 2006) . We found that inhibition of NHEJ did not depend on the presence of a 3 0 single-stranded overhang, nor did it require telomeric repeats directly adjacent to the DNA end. When 25 bp of nontelomeric DNA were placed 3 0 to 12 telomeric repeats the inhibitory effect on NHEJ was not diminished. Collectively, these results suggest that telomere protection by the RAP1/TRF2 complex must involve a directional component distinct from 3 0 end recognition of the G strand. The removal of TRF2 from telomeres results in a dramatic increase in chromosome fusions (van Steensel et al., 1998) . As TRF2 recruits RAP1 to telomeres, RAP1 would have been lost alongside TRF2 in these experiments. A general role for RAP1 in protecting telomeres from NHEJ is supported by studies in yeast. In Schizosaccharomyces pombe, ligase IV-dependent chromosome fusions accumulate in cells lacking rap1 + or taz1 + , a TRF1/2 ortholog (Miller et al., 2005) . These fusions occur specifically in G1 when NHEJ is the dominant repair pathway. In Saccharomyces cerevisiae, a Taz1/TRF2-related protein is not involved in telomere protection. Instead, RAP1 binds directly to telomeric sequences (Conrad et al., 1990; Konig et al., 1996) where it functions in telomere length regulation (Marcand et al., 1997) and prevents telomere fusions by NHEJ (Pardo and Marcand, 2005) . The conservation of RAP1 as a telomeric protein and as a negative regulator of telomere length across species suggests that a general role in NHEJ suppression may also be universal. Future experiments will need to determine whether the human RAP1/TRF2 complex specifically protects very short telomeres or is important for the protection of all telomeres from NHEJ.
EXPERIMENTAL PROCEDURES
Cell Lines and Extract Preparation GM00558 cells were obtained from the NIGMS Human Genetic Mutant Cell Repository (Camden, NJ), and HeLa S3 cells were from ATCC. GM00558 cells were grown in RPMI1640 supplemented with 15% heat-inactivated fetal bovine serum and 2 mM L-glutamine. A detailed protocol for the preparation of end-joining-competent extract can be found as Supplemental Data online. HeLa cells were grown in suspension to 9 3 10 5 cells/ml in Joklik minimal essential medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, and nonessential amino acids.
DNA and Proteins
Between 2 and 24 telomeric and scrambled repeats were introduced into the multicloning sites of pBluescript and pDEA-7Z, and constructs were sequence verified. The pDEA-7Z-derived plasmid containing (TTAGGG) 24 is referred to as pNB146 in the figure legends. Plasmids were linearized with BbsI, EcoRI, BamHI, or NotI to generate substrates with telomeric repeats at or near the 3 0 end of the G-rich strand.
Digestion with BsmBI, HindIII, and XhoI gave rise to DNA substrates with the G-rich strand at or near the 5 0 end. Linearized plasmids were dephosphorylated using calf intestine phosphatase and 32 P-la- (A) Indicated amounts of purified recombinant RAP1 were added to RAP1-depleted fraction followed by the addition of BamHI-digested pNB146 (24 telomeric repeats near the 3 0 end).
(B) Recombinant RAP1 and TRF2 were added to TRF2-or RAP1-depleted fractions.
(C) Reconstituted and purified RAP1/TRF2 complex was added to RAP1-depleted fractions prior to the addition of DNA substrates with 24 telomeric repeats at the 5 0 or 3 0 end, respectively. The amount of RAP1/TRF2 complex added is given in nanograms, as the exact stoichiometry of RAP1 and TRF2 in the complex is presently unknown.
washed in phosphate-buffered saline, and resuspended in five packed cell volumes (PCV) of buffer A (10 mM HEPES [pH 7.9]; 1.5 mM MgCl 2 ; 10 mM KCl; 0.5 mM dithiothreitol; 1 mM phenylmethylsulfonyl fluoride; 1 mg/ml of pepstatin, chymostatin, and leupeptin; and 7.5 units/l aprotinin), then incubated for 15 min on ice and collected by centrifugation. Cells were resuspended in 2 PCV of buffer A and lysed by Dounce homogenization using a loose-fitting pestle. The nuclei were collected by centrifugation, resuspended in 27.5 ml of buffer C (20 mM HEPES [pH 7.9], 25% glycerol, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM dithiothreitol, and protease inhibitors as for buffer A) and lysed by Dounce homogenization using a tight-fitting pestle. Sodium chloride was added to 0.42 M, followed by incubation on ice for 30 min. The soluble fraction was recovered by centrifugation, and ammonium sulfate was added slowly to 20% (w/v), followed by stirring on ice for 60 min. The soluble fraction was recovered by centrifugation and subjected to a second round of ammonium sulfate precipitation at 60% (NH 4 ) 2 SO 4 . Precipitated proteins were recovered by centrifugation and frozen at À80 C until use. Four pellets were combined for subsequent steps, solubilized in PK1 buffer (50 mM Tris-HCl [pH 8.0], 0.1 M KCl, 5% glycerol, 1 mM EDTA, 0.02% Tween 20, and 1 mM dithiothreitol), and dialyzed for 2.5 hr against the same buffer. The sample was cleared by centrifugation and applied onto a phosphocellulose column (Whatman P11) equilibrated with PK1. Proteins were eluted with a KCl step gradient in 0.1 M increments in the same buffer, and TRF2-containing fractions were identified by western blotting and pooled. This fraction was dialyzed against buffer T1 (25 mM HEPES [pH 7.5], 50 mM KCl, 5% glycerol, 0.5 mM EDTA, and 0.5 mM dithiothreitol) and applied to a DEAE column (Bio-Rad) equilibrated in buffer T1, and proteins were eluted with a step gradient as above. TRF2-containing fractions were diluted with 2 vol buffer T2 (20 mM potassium phosphate [pH 6.8], 5% glycerol, 0.1 mM EDTA, and 0.5 mM dithiothreitol) and applied to a monoS HR5/5 column (GE Healthcare). A linear gradient from 0 to 0.5 M KCl was applied, and TRF2-containing fractions ($0.35 M KCl) were dialyzed against T3 buffer (250 mM Tris-HCl [pH 8.0], 10% glycerol, 0.1 M KCl, 0.5 mM EDTA, and 0.5 mM dithiothreitol) and applied to a miniQ PC3.2/3 column on a SMART system (Pharmacia). A linear gradient from 0 to 0.7 M KCl was applied and TRF2 eluted around $0.35 M KCl. This fraction was either used directly in endjoining assays or subjected to size fractionation on a Superdex 200 PC3.2/30 column. His 6 -tagged TRF1 and TRF2 were expressed in baculovirus infected Sf21 cells and were purified on Ni-NTA resin (QIAGEN) and monoQ (GE Healthcare). GST-tagged human RAP1 was expressed in E. coli and purified on glutathione beads, followed by cleavage with thrombin and further purification on monoQ. For the purification of the recombinant RAP1/TRF2 complex, cleaved GST-RAP1 (7.2 mg) was incubated with TRF2 (7.5 mg) in 20 mM Tris (pH 8.0), 10% glycerol, 0.1 M KCl, and 2.5 mM b-mercaptoethanol for 3 hr at 4 C. The RAP1/TRF2 complex was then separated from uncomplexed TRF2, GST, and RAP1 degradation products on a MonoQ HR 5/5 column. Gel filtration analysis was carried out on a SMART system using a Superdex 200 PC3.2/30 column.
End-Joining Assay
Standard reactions (10 ml) contained 5 or 10 ng of EcoRI-cut DNA substrate and 15 mg of GM00558 extract. A detailed protocol is available online as Supplemental Data. For experiments with inhibitors or blocking antibodies, the extract was preincubated with the blocking agent on ice for 60 min prior to a shift to 37 C and the addition of DNA substrate.
Immunodepletion and Western Analysis
Immunodepletions were carried out in 130 ml reactions containing protein A/G beads (Calbiochem; 30 ml), 150 mg GM00558 extract in EJ buffer (50 mM tri-ethanol amine/acetic acid [pH 7.5], 60 mM potassium acetate, 0.5 mM Mg[OAc] 2 , 1 mM ATP, 1 mM dithiothreitol, and 0.1 mg/ml bovine serum albumin), and 2 mg of purified antibody or 
